TME Pharma Bags 13-month Debt Extension, Signs Two New Bond Financing Deals

03:34 AM EDT, 10/26/2026 (MT Newswires) -- TME Pharma (ALTME.PA) secured a 13-month extension for its entire outstanding debt and secured two new bond financing deals, extending its cash runway into the second quarter of 2028. The lenders of 2.4 million-euro debt agreed to extend the maturity to June 30, 2028, from May 28, 2027, the clinical-stage biotechnology company said Monday. Further, TME Pharma Chief Executive Officer Diede van den Ouden subscribed to a new non-dilutive loan of 250,000 euros. The company also secured a bond financing worth 500,000 euros from Hexagon Capital Fund.